<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04215640</url>
  </required_header>
  <id_info>
    <org_study_id>XC19DEDI0078K</org_study_id>
    <nct_id>NCT04215640</nct_id>
  </id_info>
  <brief_title>Radiofrequency Ablation of Paroxysmal Supraventricular Tachycardia Using a Novel Catheter Equipped With Mini Electrodes</brief_title>
  <official_title>Radiofrequency Ablation of Paroxysmal Supraventricular Tachycardia Using a Novel Catheter Equipped With Mini Electrodes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yong Seog Oh</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seoul St. Mary's Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Paroxysmal supraventricular tachycardia is treated with radiofrequency ablation recently.
      This procedure is performed by ablating slow pathway or accessory pathway using
      radiofrequency ablation catheter. Recently developed mirofidelity (MIFI) catheter has
      mini-electrodes that can record local eletrogram with higher resolution. We aimed to
      investigate the efficacy of MIFI catheter in the ablation of paroxysmal supraventricular
      tachycardia compared to conventional radiofrequency ablation catheter. Enrolled patients
      undergo conventional electrophysiologic study. Patients with sustained supraventricular
      tachycardia during the study are randomized to either study group or control group.
      Radiofrequency ablation is performed using MIFI catheter in the study group, and conventional
      catheter (Blazer II) in the control group. The study endpoints are recorded immediately after
      ablation and there is no additional follow up or management after procedure.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 13, 2020</start_date>
  <completion_date type="Anticipated">June 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>RF time (seconds) to successful ablation</measure>
    <time_frame>At the end of radiofrequency ablation procedure</time_frame>
    <description>For AVNRT, the time (seconds) from the beginning of radiofrequency ablation to the emergence of junctional rhythm For AVRT, the time (seconds) from the beginning of radiofrequency ablation to the accessory pathway block</description>
  </primary_outcome>
  <primary_outcome>
    <measure>RF application number</measure>
    <time_frame>At the end of radiofrequency ablation procedure</time_frame>
    <description>Number of radiofrequency ablation attempt to successful ablation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Total ablation time (seconds)</measure>
    <time_frame>At the end of radiofrequency ablation procedure</time_frame>
    <description>Total time of radiofrequency energy delivery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence of either acute reconnection or reinduction</measure>
    <time_frame>At the end of radiofrequency ablation procedure</time_frame>
    <description>Acute accessory pathway reconnection or supraventricular tachycardia reinduction after ablation</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Paroxysmal Supraventricular Tachycardia</condition>
  <arm_group>
    <arm_group_label>MIFI group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients in the MIFI group receive standard radiofrequency ablation procedure for the supraventricular tachycardia using microfidelity (MIFI) catheter.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients in the control group receive standard radiofrequency ablation procedure for the supraventricular tachycardia using conventional ablation catheter (Blazer II).</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Microfidelity (MIFI) catheter</intervention_name>
    <description>Patients are randomized into the MIFI group and control group. Radiofrequency ablation will target slow pathway for AVNRT or accessory pathway for AVRT. Microfidelity (MIFI) catheter equipped with mini-electrodes will be used for ablation in the MIFI group.</description>
    <arm_group_label>MIFI group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Conventional ablation catheter</intervention_name>
    <description>Patients are randomized into the MIFI group and control group. Radiofrequency ablation will target slow pathway for AVNRT or accessory pathway for AVRT. Blazer II radiofrequency ablation catheter will be used for ablation in the control group.</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients who are scheduled to undergo radiofrequency ablation for paroxysmal
             supraventricular tachycardia or WPW syndrome with atrial fibrillation

          -  Give written informed consent for the study

        Exclusion Criteria:

          -  Unable to induce supraventricular tachycardia during electrophysiologic study.

          -  Cognitive impairment to understand study procedure
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yong-Seog Oh</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul St. Mary's Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sung-Hwan Kim, MD,PhD</last_name>
    <phone>+82-2-3779-1325</phone>
    <email>sunghwan@catholic.ac.kr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Seoul St Mary's Hospital</name>
      <address>
        <city>Seoul</city>
        <state>Seo Ch-gu</state>
        <zip>137-701</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sung Hwan Kim, MD</last_name>
      <phone>82-10-9109-8957</phone>
      <email>sunghwan@catholic.ac.kr</email>
    </contact>
    <investigator>
      <last_name>Yong Seog Oh, Ph.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>December 30, 2019</study_first_submitted>
  <study_first_submitted_qc>December 30, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 2, 2020</study_first_posted>
  <last_update_submitted>April 20, 2020</last_update_submitted>
  <last_update_submitted_qc>April 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Seoul St. Mary's Hospital</investigator_affiliation>
    <investigator_full_name>Yong Seog Oh</investigator_full_name>
    <investigator_title>professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tachycardia</mesh_term>
    <mesh_term>Tachycardia, Supraventricular</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>IPD would be provided with an appropriate request from other investigators.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

